PD-related psychosis: Pathophysiology with therapeutical strategies

Journal of Neural Transmission, Supplement

Volumn , Issue 71, 2006, Pages 31-37

  Wolters, E Ch ^a,b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; DOPAMINE; GALANTAMINE; NEUROTRANSMITTER; OLANZAPINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; TACRINE;

AGRANULOCYTOSIS; ALZHEIMER DISEASE; ANOREXIA; AUDITORY HALLUCINATION; AUTONOMIC DYSFUNCTION; BRADYKINESIA; CHOLINERGIC SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CORPUS STRIATUM; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC NERVE CELL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; HUMAN; HYPERSALIVATION; HYPOKINESIA; HYPOSMIA; LIVER TOXICITY; LOW DRUG DOSE; MENTAL DETERIORATION; NAUSEA AND VOMITING; NORADRENERGIC SYSTEM; ORTHOSTATIC HYPOTENSION; PARANOIA; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RIGIDITY; SEDATION; SIDE EFFECT; SLEEP DISORDER; SUBSTANTIA NIGRA; TACHYCARDIA; TREMOR; UNSPECIFIED SIDE EFFECT; VISUAL HALLUCINATION;

HUMANS; PARKINSON DISEASE; PSYCHOTIC DISORDERS;

EID: 34248571822     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-33328-0_4     Document Type: Review

References (75)

1. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E (1999a) Mental Symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 14: 866-874
2. Aarsland D, Bronnick K, Karlsen K (1999b) Donepezil for dementia with Lewy bodies: a case study. Int J Geriatr Psychiatry 14: 69-72
3. Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 48: 938-942
4. Aarsland D, Hutchinson M, Larsen JP (2003) Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 18: 937-941
5. Alexander GE, Delong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9: 357-381
6. Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhaen D, Derenne JP, Agid Y (2000) Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 55: 281-288
7. Ballard C, Grace J, McKeith I, Holmes C (1998) Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 351: 1032-1033
8. Bartorelli L, Giraldi C, Saccardo M, Cammarata S, Bottini G, Fasarano AM, Trequattrini A (2005) Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin 21: 1809-1818
9. Bergman J, Lerner V (2002) Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 25: 107-110
10. Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH (2002) Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 52: 438-445
11. Bullock R, Cameron A (2002) Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 18: 258-264
12. Bullock R (2004) Galantamine: use in Alzheimer's disease and related disorders. Expert Rev Neurother 4: 153-163
13. Comella CL, Tanner CM, Ristanovic RK (1993) Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 34: 710-714
14. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B (1998) Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group. Neurology 50: 1214-1221
15. Davies P, Maloney AJF (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403
16. Dubois B, Pillon B (1997) Cognitive deficits in Parkinson's disease. J Neurol 244: 2-8
17. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH (2000) Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 12: 364-369
18. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevski J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R (2004) Rivastigmine for the dementia associated with Parkinson's disease. N Engl J Med 351: 2509-2518
19. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G (2002) Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 23: 41-43
20. Fergusson E, Howard R (2000) Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int J Geriatr Psychiatry 15: 280-281
21. Fernandez HH, Lannon MC, Friedman JH, Abbott BP (2000) Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 15: 579-581
22. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH (2003) Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 18: 510-514
23. Friedman JH, Wagner RL (1987) Symptoms of neuroleptic malignant syndrome. Am J Psychiatry 144: 1105-1106
24. Gabelli C (2003) Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions. Curr Med Res Opin 19: 69-82
25. Goetz CG, Tanner CM, Klawans HL (1982) Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 139: 494-497
26. Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43: 2227-2229
27. Grace J, Daniel S, Stevens T, Shankar KK, Walker Z, Byrne EJ, Butter S, Wilkinson D, Wodford J, Waite J, McKeith IG (2001) Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 13: 199-205
28. Graham JM, Grunewald RA, Sagar HJ (1997) Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 63: 434-440
29. Harding AJ, Halliday GM (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 102: 355-363
30. Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 70: 734-738
31. Hutchinson M, Fazzini E (1996) Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 61: 324-325
32. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H (2005) Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. B M J 331: 321-327
33. Karlsen KH, Larsen JP, Tandberg E, Maland JG (1998) Quality of life measurements in patients with Parkinson's disease: A community-based study. Eur J Neurol 5: 443-450
34. Kaufer DI, Catt KE, Lopez OL, DeKosky ST (1998) Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology 51: 1512
35. Keyser DL, Rodnitzky RL (1991) Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med 151: 794-796
36. Klawans HL, Goetz C, Nausieda PA, Weiner WJ (1977) Levodopa-induced dopamine receptor hypersensitivity. Trans Am Neurol Assoc 102: 80-83
37. Knable MB, Heinz A, Raedler T, Weinberger DR (1997) Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res 75: 91-101
38. Lauterbach EC (1991) Serotonin reuptake inhibitors, paranoia, and the ventral basal ganglia. Clin Neuropharmacol 14: 547-555
39. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E (1992) Neuroleptic sensitivity in patients with senile dementia of Lewy body type. B M J 305: 673-678
40. McKeith IG, Ballard CG, Harrison RWS (1995) Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 346: 699
41. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen ENH, Ballard C, deVos RAI, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124
42. McKeith IG (2000) Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin 18: 865-902
43. McKeith I, del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356: 2031-2036
44. Melamed E, Zoldan J, Friedberg G, Ziv I, Weizmann A (1996) Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Adv Neurol 69: 545-550
45. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251: 238-246
46. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors : their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 1159-1172
47. Moskovitz C, Moses H III, Klawans HL (1978) Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 135: 669-675
48. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J (2002) Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 17: 1031-1035
49. Pappert EJ, Goetz CG, Niederman FG, Raman R, Leurgans S (1999) Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord 14: 117-121
50. Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 50: 743-755
51. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn A, Tomlinson BE, Perry RH (1985) Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 48: 413-421
52. Perry EK, McKeith I, Thompson P, Marshall E, Kerwin J, Jabeen S, Edwardson JA, Ince P, Blessed G, Irving D, Perry RH (1991) Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann N Y Acad Sci 640: 197-202
53. Perry EK, Irving D, Kerwin JM, McKeith I, Thompson P, Collerton D, Fairbairn A, Ince PG, Morris CM, Cheng AV, Perry RH (1993) Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 7: 69-79
54. Perry EK, Perry RH (1995) Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 28: 240-258
55. Perry E, Walker M, Grace J, Perry R (1999) Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 22: 273-280
56. Poewe W (2003) Psychosis in Parkinson's disease. Mov Disord 18 [Suppl 6]: S80-S87
57. Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, Lane R (2006) Long term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord: In press
58. Reading PJ, Luce AK, McKeith IG (2001) Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 16: 1171-1174
59. Rich SS, Friedman JH, Ott BR (1995) Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 56: 556-559
60. Rondot P, de Recondo J, Coignet A, Ziegler M (1984) Mental disorders in Parkinson's disease after treatment with L-DOPA. Adv Neurol 40: 259-269
61. Saint-Cyr JA, Taylor AE, Lang AE (1993) Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 43: S47-S52
62. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47: 27-38
63. Shea C, MacKnight C, Rockwood K (1998) Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 10: 229-238
64. Shimomura T, Mori E, Yamashita H, Imamura T, Hirono N, Hashimoto M, Tanimukai S, Kazui H, Hanihara T (1998) Cognitive loss in dementia with Lewy bodies and Alzheimer disease. Arch Neurol 55: 1547-1552
65. Stam CJ, Visser SL, Op de Coul AAW, deSonneVille LMJ, Schellens RLLA, Brunia CHM, Desmet JS, Gielen G (1993) Disturbed frontal regulation of attention in Parkinson's disease. Brain 116: 1139-1158
66. Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, Green C (2006) A systematic review of the clinical effectiviness of donezepil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 21: 17-28
67. The French Clozapine Parkinson Study Group (1999) Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 353: 2041-2042
68. The Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340: 757-763
69. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R (2005) benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 65: 1654-1656
70. 123I]β-CIT SPECT study in early nonmedicated patients. Mov Disord 16: 1033-1040
71. Wolters EC, Jansen ENH, Tuynman-Qua HG, Bergmans PLM (1996) Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 47: 1085-1087
72. Wolters EC, Francot CMJE (1998) Mental dysfunctions in Parkinson's disease. Parkinsonism Relat Disord 4: 107-112
73. Wolters EC (2001) Psychiatric complications in the treatment of Parkinson's disease. Adv Neurol 86: 385-393
74. Wolters ECh, Braak (2006) Clinico-pathological correlations in Parkinson's disease. J Neural Transm: In press
75. Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL (1989) The pedunculopontine nucleus in Parkinson's disease. Ann Neurol 26: 41-46